A Study to Access the Safety/Efficacy of Thalidomide in the Treatment of Anemia in Patients With Myelodysplastic Syndromes

Inclusion Criteria

• •Eligible patients must have a diagnosis of myelodysplastic syndrome
• •Life expectancy of at least 6 months.
• •Patients must be able to adhere to the study visit schedule and other protocol requirements.
• •Patients must understand and voluntarily sign an informed consent document.
• •Women of childbearing potential (WCBP) must agree to practice abstinence or to use TWO methods of contraception beginning 4 weeks prior to the start of study medication and throughout the course of treatment.
• •Males must use barrier contraception when engaging in reproductive sexual activity with women of childbearing potential.